GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study


      • NME1 and EGFR were the candidate genes most strongly associated with progression in this endometrial cancer patient cohort.
      • SNP rs13222385 in EGFR also remained significant after adjusting for prognostic clinical variables.
      • Although hypothesis generating, further work is needed to validate these findings and assess for other predictive SNPs.



      The ability to stratify a patient's risk of metastasis and survival permits more refined care. A proof of principle study was undertaken to investigate the relationship between single nucleotide polymorphisms (SNPs) in literature based candidate cancer genes and the risk of nodal metastasis and clinical outcome in endometrioid endometrial cancer (EEC) patients.


      Surgically-staged EEC patients from the Gynecologic Oncology Group or Washington University School of Medicine with germline DNA available were eligible. Fifty-four genes represented by 384 SNPs, were evaluated by Illumina Custom GoldenGate array. Association with lymph node metastases was the primary outcome. Progression-free survival (PFS) and overall survival (OS) was also evaluated.


      361 SNPs with high quality genotype data were evaluated in 337 patients with outcome data. Five SNPs in CXCR2 had an odds ratio (OR) between 0.68 and 0.70 (p-value ≤ 0.025). The A allele rs946486 in ABL had an OR of 1.5 (p-value = 0.01) for metastasis. The G allele in rs7795743 in EGFR had an OR for metastasis of 0.68 (p-value = 0.02) and hazard ratio (HR) for progression of 0.66 (p-value = 0.004). Importantly, no SNP met genome wide significance after adjusting for multiple test correcting and clinical covariates. The A allele in rs2159359 SNP in NME1 and the G allele in rs13222385 in EGFR were associated with worse OS. Both exhibited genome wide significance; rs13222385 remained significant after adjusting for prognostic clinical variables.


      SNPs in cancer genes including rs2159359 SNP in NME1 and rs13222385 in EGFR may stratify risk in EEC and are prioritized for further investigation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J. Clin. 2018; 68: 7-30
        • Creasman W.T.
        • Morrow C.P.
        • Bundy B.N.
        • Homesley H.D.
        • Graham J.E.
        • Heller P.B.
        Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.
        Cancer. 1987; 60: 2035-2041
        • Bidus M.A.
        • Risinger J.I.
        • Chandramouli G.V.
        • Dainty L.A.
        • Litzi T.J.
        • Berchuck A.
        • et al.
        Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray.
        Clin. Cancer Res. 2006; 12: 83-88
        • Benedetti Panici P.
        • Basile S.
        • Maneschi F.
        • Alberto Lissoni A.
        • Signorelli M.
        • Scambia G.
        • et al.
        Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
        J. Natl. Cancer Inst. 2008; 100: 1707-1716
        • A.s
        group, Kitchener H., Swart A.M., Qian Q., Amos C., Parmar M.K. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.
        Lancet. 2009; 373: 125-136
        • Randall M.E.
        • Filiaci V.L.
        • Muss H.
        • Spirtos N.M.
        • Mannel R.S.
        • Fowler J.
        • et al.
        Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
        J. Clin. Oncol. 2006; 24: 36-44
        • Mundt A.J.
        • McBride R.
        • Rotmensch J.
        • Waggoner S.E.
        • Yamada S.D.
        • Connell P.P.
        Significant pelvic recurrence in high-risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy.
        Int. J. Radiat. Oncol. Biol. Phys. 2001; 50: 1145-1153
        • Sartori E.
        • Laface B.
        • Gadducci A.
        • Maggino T.
        • Zola P.
        • Landoni F.
        • et al.
        Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study.
        Int. J. Gynecol. Cancer. 2003; 13: 458-465
        • Todo Y.
        • Yamamoto R.
        • Minobe S.
        • Suzuki Y.
        • Takeshi U.
        • Nakatani M.
        • et al.
        Risk factors for postoperative lower-extremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy.
        Gynecol. Oncol. 2010; 119: 60-64
        • Hsieh S.M.
        • Lintell N.A.
        • Hunter K.W.
        Germline polymorphisms are potential metastasis risk and prognosis markers in breast cancer.
        Breast Dis. 2006; 26: 157-162
        • Hunter K.
        The intersection of inheritance and metastasis: the role and implications of germline polymorphism in tumor dissemination.
        Cell Cycle. 2005; 4: 1719-1721
        • Hunter K.W.
        Allelic diversity in the host genetic background may be an important determinant in tumor metastatic dissemination.
        Cancer Lett. 2003; 200: 97-105
        • Ramaswamy S.
        • Ross K.N.
        • Lander E.S.
        • Golub T.R.
        A molecular signature of metastasis in primary solid tumors.
        Nat. Genet. 2003; 33: 49-54
        • Acosta J.C.
        Gil J. A role for CXCR2 in senescence, but what about in cancer?.
        Cancer Res. 2009; 69: 2167-2170
        • Schultheis A.M.
        • Lurje G.
        • Rhodes K.E.
        • Zhang W.
        • Yang D.
        • Garcia A.A.
        • et al.
        Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.
        Clin. Cancer Res. 2008; 14: 7554-7563
        • Bondurant K.L.
        • Lundgreen A.
        • Herrick J.S.
        • Kadlubar S.
        • Wolff R.K.
        • Slattery M.L.
        Interleukin genes and associations with colon and rectal cancer risk and overall survival.
        International journal of cancer Journal international du cancer. 2013; 132: 905-915
        • Snoussi K.
        • Mahfoudh W.
        • Bouaouina N.
        • Fekih M.
        • Khairi H.
        • Helal A.N.
        • et al.
        Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.
        BMC Cancer. 2010; 10: 283
        • Yang H.P.
        • Woodson K.
        • Taylor P.R.
        • Pietinen P.
        • Albanes D.
        • Virtamo J.
        • et al.
        Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial.
        European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation. 2006; 15: 249-253
      1. J. Colicelli. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal. 2010;3:re6.

        • Wu I.C.
        • Zhao Y.
        • Zhai R.
        • Liu G.
        • Ter-Minassian M.
        • Asomaning K.
        • et al.
        Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma.
        Neoplasia. 2011; 13: 386-392
        • Cunningham J.M.
        • Vierkant R.A.
        • Sellers T.A.
        • Phelan C.
        • Rider D.N.
        • Liebow M.
        • et al.
        Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.
        Br. J. Cancer. 2009; 101: 1461-1468
        • Aranaz P.
        • Ormazabal C.
        • Hurtado C.
        • Erquiaga I.
        • Calasanz M.J.
        • Garcia-Delgado M.
        • et al.
        A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.
        Cancer Genet. Cytogenet. 2010; 199: 1-8
        • Bansal N.
        • Yendluri V.
        • Wenham R.M.
        The molecular biology of endometrial cancers and the implications for pathogenesis, classification.
        and targeted therapies. Cancer control: journal of the Moffitt Cancer Center. 2009; 16: 8-13
        • LaFramboise T.
        • Dewal N.
        • Wilkins K.
        Pe'er I., Freedman M.L. Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis.
        PLoS Genet. 2010; 6e1001086
        • Zeng M.
        • van der Donk W.A.
        • Chen J.
        Lanthionine synthetase C-like protein 2 (LanCL2) is a novel regulator of Akt.
        Mol. Biol. Cell. 2014; 25: 3954-3961
        • da Cunha Santos G.
        • Shepherd F.A.
        Tsao M.S. EGFR mutations and lung cancer.
        Annu. Rev. Pathol. 2011; 6: 49-69
        • Fleming G.F.
        • Sill M.W.
        • Darcy K.M.
        • McMeekin D.S.
        • Thigpen J.T.
        • Adler L.M.
        • et al.
        Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2010; 116: 15-20
        • Royds J.A.
        • Rees R.C.
        Stephenson T.J. nm23--a metastasis suppressor gene?.
        J. Pathol. 1994; 173: 211-212
        • Bevilacqua G.
        • Sobel M.E.
        • Liotta L.A.
        • Steeg P.S.
        Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential.
        Cancer Res. 1989; 49: 5185-5190
        • Florenes V.A.
        • Aamdal S.
        • Myklebost O.
        • Maelandsmo G.M.
        • Bruland O.S.
        • Fodstad O.
        Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression.
        Cancer Res. 1992; 52: 6088-6091
        • Marone M.
        • Scambia G.
        • Ferrandina G.
        • Giannitelli C.
        • Benedetti-Panici P.
        • Iacovella S.
        • et al.
        Nm23 expression in endometrial and cervical cancer: inverse correlation with lymph node involvement and myometrial invasion.
        Br. J. Cancer. 1996; 74: 1063-1068
        • Jaakkola S.
        • Salmikangas P.
        • Nylund S.
        • Partanen J.
        • Armstrong E.
        • Pyrhonen S.
        • et al.
        Amplification of fgfr4 gene in human breast and gynecological cancers.
        International journal of cancer Journal international du cancer. 1993; 54: 378-382
        • Lacey Jr., J.V.
        • Yang H.
        • Gaudet M.M.
        • Dunning A.
        • Lissowska J.
        • Sherman M.E.
        • et al.
        Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study.
        Gynecol. Oncol. 2011; 120: 167-173
        • Shastry B.S.
        Genetic diversity and new therapeutic concepts.
        J. Hum. Genet. 2005; 50: 321-328
        • Sousa V.
        • Hey J.
        Understanding the origin of species with genome-scale data: modelling gene flow.
        Nat. Rev. Genet. 2013; 14: 404-414
        • Kopec J.A.
        • Esdaile J.M.
        Bias in case-control studies.
        A review. Journal of epidemiology and community health. 1990; 44: 179-186